Consistency assessment and disposition in vivo after oral administration of celecoxib capsules to Beagle dogs

Abstract

Abstract: AIM: Establish an HPLC method for the determination of celecoxib in dog plasma. Besides evaluate in vivo disposition consistency by comparing their pharmacokinetic parameters after oral administration of celecoxib capsules or Celebrex to Beagle dogs.METHODS: According to a two-period crossover design, 8 Beagle dogs received a single oral dose of test or reference capsules, respectively. The plasma concentration of celecoxib was determined by the established HPLC method. The pharmacokinetic parameters and relative bioavailability were calculated.RESULTS: The relative bioavailability of celecoxib was (106.0±26.7) %. Based on the analysis of variance, two-sided t-test and rank sum test of the pharmacokinetic parameters including t_max, C_max, and AUC_(0→t), there were no significant difference between both preparations (P>0.05).CONCLUSION: The disposition in vivo of celecoxib capsules is in consistency with that of Celebrex.

Key words: Celecoxib, Bioavailability, High performance liquid chromatography

CLC Number:

R969

CUI Tao, GAO Jing, YI Xiu-lin, ZENG Yong, LI Wei, SI Duan-yun. Consistency assessment and disposition in vivo after oral administration of celecoxib capsules to Beagle dogs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 371-375.

References

[1] 柯中古, 王槐武, 郑和国, 等. 反相高效液相色谱法测定塞来昔布片含量[J]. 中国医院药学杂志, 2003, 23(4): 205-207.
[2] Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis[J]. JAMA, 2000, 284(10): 1247-1255.
[3] Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis[J]. Am J Gastroenterol, 2001, 96(4): 1019-1027.
[4] Schönberger F, Heinkele G, Mürdter TE, et al. Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2002, 768(2): 255-260.
[5] Werner U, Werner D, Pahl A, et al. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry[J]. Biomed Chromatogr, 2002, 16(1): 56-60.
[6] Barrientos-Astigarraga RE, Vannuchi YB, Sucupira M, et al. Quantification of nimesulide in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Application to bioequivalence studies[J]. J Mass Spectrom, 2001, 36(12): 1281-1286.
[7] Kempen EC, Yang P, Felix E, et al. Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry[J]. Anal Biochem, 2001, 297(2): 183-190.
[8] Störmer E, Bauer S, Kirchheiner J, et al. Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 783(1): 207-212.
[9] 温预关, 蔡素华, 陈国中, 等. 高效液相色谱法测定人血浆中塞来昔布的浓度[J]. 中国医院药学杂志, 2004, 24(10): 602-604.
[10] Nasr M. In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration[J]. AAPS PharmSciTech, 2010, 11(1): 85-89.
[11] Liu Y, Sun C, Hao Y, et al. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles[J]. J Pharm Pharm Sci, 2010, 13(4): 589-606.
[12] Shakeel F, Baboota S, Ahuja A, et al. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion[J]. J Nanobiotechnol, 2008, 6:8.

[1]	HE Jie, LIU Dongxue, ZHONG Lingjun, SHAO Hua, HU Linlin. Establishment of a limited sampling strategy to estimate micafungin exposure in critically ill patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1264-1271.
[2]	LI Zhihui, LIU Jingyan, QIU Wen, CHEN Hong. Bioequivalence of fluconazole capsules in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 910-915.
[3]	PAN Zhanhe, WANG Xin, SU An, ZHANG Peng, JI Haonan, WANG Xiaomei. Mechanism of celecoxib reverses adriamycin resistance in NK/T cell lymphoma cells by Notch 1/NF-κB/STAT3 pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1330-1336.
[4]	ZOU Quan-fei, LU Rong, FAN Hui-rong, ZHAO Guang-rong, ZHANG Tie-jun, SI Duan-yun. Study of pharmacokinetics and bioavailability of scicinib in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 254-259.
[5]	ZHANG Yi-wen, CHEN Yao, TAN Zhi-rong, YU Jing, PENG Jing-bo, OU YANG Dong-sheng, ZHOU Hong-hao. Study of pharmacokinetics and relative bioequivalence of single and multiple oral doses of ibuprofen sustained-release capsules [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 297-301.
[6]	ZHANG Chang-feng, ZHENG Xian-he, HU Shuang-yan, CHEN Nian-ping, LI Yu-hong. Effects of premedication with celecoxib and pregabalin on postoperative pain in the elderly orthopedic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 1039-1043.
[7]	TIAN Wei-chao, YANG Rui, SHEN Jie, XIE Hai-tang, WANG Fang-jie, XIAO Jian. Study of the relative bioequivalence of sustained release capsules of Ibuprofen in healthy volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(5): 545-549.
[8]	LUO Xi, CAI Ning-fang, GUO Xin, YU Peng, LIU Zhi, ZHENG Li-yun, CHENG Ze-neng. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamine hydrochloride after oral administration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(12): 1375-1382.
[9]	ZHONG Guo-ping¹, CHEN Xiao², REN Bin², ZHONG Shi-long³, KUANG Cui-yi², HUANG Li-hui¹, ZENG Gui-xiong¹, WANG Xue-ding¹, LIAO Xiao-xing², HUANG Min¹, ZHAO Xiang-lan¹. Single-dose and multi-dose pharmacokinetics and bioavailability of ofloxacin sustained-release tablets in healthy volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(11): 1260-1265.
[10]	ZHU Jing, GUO Jian-jun, LIN Jun-hui, BU Hai-zhi, CHEN Xi-jing. Research advances in models of hepatic and intestinal first-pass drug metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(8): 944-949.
[11]	SUN Jia-lin, SONG Jun-ke, XING Cheng, LV Yang, DU Guan-hua. Pharmacokinetics of different nitrendipine tablets in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 755-760.
[12]	WU Li-nan, LU Rong, GU Yuan, LIU Chang-xiao, SI Duan-yun. Pharmacokinetics and bioavalibability of catalpol in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 126-130.
[13]	LI Rui-xing, FAN Hui-rong, WEI Guang-li, REN Xiao-wen, SI Duan-yun, LIU Chang-xiao. LC-MS/MS determination of torasemide in Beagle dog plasma and bioavailability evaluation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 199-205.
[14]	WANG Da-wei, LI Feng, XU Ping, ZHOU Lei, LIU Li, LIU Xiao-dong. Pharmacokinetics of clematichinenoside AR and its absolute bioavailability in Beagle dogs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(11): 1211-1215.
[15]	WANG Xiao-bo, XI Rong-gang, ZHENG Hui-min, YUE Hong, LIU Dan. Bioequivalence of tosufloxacin tosylate tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(2): 180-184.